Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5- b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase

Journal of Medicinal Chemistry

Volumn 42, Issue 26, 1999, Pages 5464-5474

  Showalter, H D Hollis ^a   Bridges, Alexander J ^a   Zhou, Hairong ^a   Sercel, Anthony D ^a   McMichael, Amy ^a   Fry, David W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; BINDING SITE; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHARMACOPHORE; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; ENZYME INHIBITORS; HUMANS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033619989     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9903949     Document Type: Article

References (42)

1. Messa, C.; Russo, F.; Caruso, M. G.; DiLeo, A. EGF, TGF-α, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998, 37, 285-289.
2. Reese, D. M.; Slamon, D. J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997, 15, 1-8.
3. Revillion, F.; Bonneterre, J.; Peyrat, J. P. ERB-B2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 1998, 34, 791-808.
4. Hynes, N. E.; Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta-Rev. Cancer 1994, 1198, 165-184.
5. Bridges, A. J. The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target? Curr. Med. Chem. 1996, 3, 167-196.
6. Khazaie, K.; Schirrmacher, V.; Lichtner, R. B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. 1993, 12, 255-274.
7. Davies, D. E.; Chamberlin, S. G. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem. Pharmacol. 1996, 51, 1101-1110.
8. Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines. Bioorg. Med. Chem Lett. 1997, 7, 2723-2728.
9. Levitzki, A.; Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267, 1782-1788.
10. Traxler, P. M. Protein tyrosine kinase inhibitors in cancer treatment. Expert Opin. Ther. Patents 1997, 7, 571-588.
11. Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, T.; Mueller, M.; Regenass, U.; Rihs, G.; Lydon, N.; Traxler, P. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1994, 37, 1015-1027.
12. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; Diorio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57, 4838-4848.
13. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrole- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
14. Traxler, P.; Bold, G.; Frei, J.; Lang, M.; Lydon, N.; Mett, H.; Buchdunger, E.; Meyer, T.; Mueller, M.; Furet, P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 1997, 40, 3601-3616.
15. Lydon, N. B.; Mett, H.; Mueller, M.; Becker, M.; Cozens, R. M.; Stover, D.; Daniels, D.; Traxler, P.; Buchdunger, E. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int. J. Cancer 1998, 76, 154-163.
16. Thomas, A. P. 4,6-Dianilinopyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors. World Pat. Appl. WO 95/15952, 1995.
17. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase - investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
18. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase Science 1994, 265, 1093-1095.
19. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1996, 39, 2285-2292.
20. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
21. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 918-928.
22. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
23. Monge, A.; Palop, J. A.; Goni, T.; Martinez-Crespo, F.; Recalde, I.; Fernandez-Alvarez, E. Synthesis of 4-hydrazino-5H-pyrimido-[5,4-b]indole and related compounds. J. Heterocycl. Chem. 1986, 23, 647-649.
24. Kadushkin, A. V.; Nesterova, I. N.; Golovko, T. V.; Nikolaeva, I. S.; Pushkina, T. V.; Fomina, A. N.; Sokolova, A. S.; Chernov, V. A.; Granik, V. G. Condensed pyrrolo[3,2-d]pyrimidines: synthesis and biological activity. Khim.-Farm. Zh. 1990, 24, 18-22; Chem. Abstr. 1991, 114, 164140.
25. Kadushkin, A. V.; Nesterova, I. N.; Golovko, T. V.; Nikolaeva, I. S.; Pushkina, T. V.; Fomina, A. N.; Sokolova, A. S.; Chernov, V. A.; Granik, V. G. Condensed pyrrolo[3,2-d]pyrimidines: synthesis and biological activity. Khim.-Farm. Zh. 1990, 24, 18-22; Chem. Abstr. 1991, 114, 164140.
26. Grob, C. A.; Weissbach, O. The preparation of oxindole derivatives from o-chloronitrobenzene and cyanoacetic acid or malonic esters. Helv. Chim. Acta 1981, 44, 1748-1753.
27. Glushkov, R. G.; Volskova, V. A.; Magidson, O. Y. 2-Aminocarboxyethylindole and its derivatives. Khim.-Farm. Zh. 1966, 1, 25-32; Chem. Abstr. 1967, 68, 105143.
28. Glushkov, R. G.; Volskova, V. A.; Magidson, O. Y. 2-Aminocarboxyethylindole and its derivatives. Khim.-Farm. Zh. 1966, 1, 25-32; Chem. Abstr. 1967, 68, 105143.
29. Venugopalan, B.; Desai, P. D.; de Souza, N. J. Synthesis of 6,7-dimethoxypyrimido[4,5-b]indoles as potential antihypertensive agents. J. Heterocycl. Chem. 1988, 25, 1633-1639.
30. Portnov, Y. N.; Bulaga, S. N.; Zabrodnyaya, V. G.; Smirnov, L. D. Synthesis of 9H-pyrimido[4,5-b]indoles from 2-amino-3-cyanoindoles. Khim. Geterotsikl. Soedin. 1991, 3, 400-402; Chem. Abstr. 1992, 115, 136045.
31. Portnov, Y. N.; Bulaga, S. N.; Zabrodnyaya, V. G.; Smirnov, L. D. Synthesis of 9H-pyrimido[4,5-b]indoles from 2-amino-3-cyanoindoles. Khim. Geterotsikl. Soedin. 1991, 3, 400-402; Chem. Abstr. 1992, 115, 136045.
32. Robba, M.; Touzot, P.; Riquelme, R. M. Synthese de benzo(1)-thieno[2,3-d]pyrimidines et de benzo(1)thieno[3,2-d]pyrimidines. Tetrahedron Lett. 1972, 44, 4549-4551.
33. Robba, M.; Touzot, P.; El-Kashef, H. [1]Benzothienopyrimidines. I. Etude de la 3H-benzothieno[3,2-d]pyrimidone-4. J. Heterocycl. Chem. 1980, 17, 923-928.
34. Bridges, A. J.; Zhou, H. Synthetic methodology for the preparation of benzo[b]thieno[3,2-d]pyrimidines substituted with electron donating substituents on the benzene ring. J. Heterocycl. Chem. 1997, 34, 1134-1139.
35. Scheibye, S.; Pedersen, B. S.; Lawesson, S.-O. The dimer of p-methoxyphenylthionophosphine sulfide as thiation reagent. A new route to thiocarboxamides. Bull. Soc. Chim. Belg. 1978, 87, 229-233.
36. Clarke, H. T.; Gillespie, H. H.; Weishaus, S. Z. The action of formaldehyde on amines and amino acids. J. Am. Chem. Soc. 1933, 55, 4571.
37. Athmani, S.; Iddon, B. Thiazolo[4′,5′:4,5]thieno[3,2-d]pyrimidine, a new heterocyclic system. Tetrahedron 1992, 48, 7689-7702.
38. Gewald, K.; Neumann, G.; Brettcher, H. Heterocycles from CH-acidic nitriles: XI. New synthesis of 2-aminothianaphthene. Chem. Ber. 1966, 99, 261.
39. Bridges, A. J.; Cody, D. R.; Zhou, H.; McMichael, A.; Fry, D. W. Enantioselective inhibition of the EGF receptor tyrosine kinase by 4-(α-phenethylamino)quinazoline derivatives. Bioorg. Med. Chem. 1995, 3, 1651-1656.
40. Halfpenny, P. R.; Horwell, D. C.; Hughes, J.; Hunter, J. C.; Rees, D. C. Highly selective kappa-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted-cyclohexyl]arylacetamide derivatives. J. Med. Chem. 1990, 33, 286-291.
41. Yokoyama, M.; Yoshida, S.; Imamoto, S. Organic reactions using trimethylsilyl polyphosphate (PPSE): a convenient synthesis of nitriles from carboxamides. Synthesis 1982, 591-592.
42. Gill, G. N.; Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol. 1987, 146, 82-88.